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Abstract
Background: Loss of DNA mismatch repair (MMR) in humans, mainly due to mutations in the
hMLH1 gene, is linked to hereditary nonpolyposis colorectal cancer (HNPCC). Because not all
MLH1 alterations result in loss of MMR function, accurate characterization of variants and their
classification in terms of their effect on MMR function is essential for reliable genetic testing and
effective treatment. To date, in vivo assays for functional characterization of MLH1 mutations
performed in various model systems have used episomal expression of the modified MMR genes.
We describe here a novel approach to determine accurately the functional significance of hMLH1
mutations in vivo, based on co-expression of human MLH1 and PMS2 in yeast cells.
Methods: Yeast MLH1 and PMS1 genes, whose protein products form the MutLα complex, were
replaced by human orthologs directly on yeast chromosomes by homologous recombination, and
the resulting MMR activity was tested.
Results: The yeast strain co-expressing hMLH1 and hPMS2 exhibited the same mutation rate as
the wild-type. Eight cancer-related MLH1 variants were introduced, using the same approach, into
the prepared yeast model, and their effect on MMR function was determined. Five variants (A92P,
S93G, I219V, K618R and K618T) were classified as non-pathogenic, whereas variants T117M,
Y646C and R659Q were characterized as pathogenic.
Conclusion: Results of our in vivo yeast-based approach correlate well with clinical data in five out
of seven hMLH1 variants and the described model was thus shown to be useful for functional
characterization of MLH1 variants in cancer patients found throughout the entire coding region of
the gene.
Background
Mismatch repair (MMR) genes are genome-stability genes.
Mutations in these genes cause defects in the MMR path-
way that can lead to carcinogenesis, as a result of accumu-
lation of non-repaired post-replicational mis-
incorporations in cancer contributing genes. Inherited
germline mutations of MMR genes cause a predisposition
to cancer, which can develop at an early age, as the next
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allele of a gene [1,2]. It has been established that many
families with hereditary non-polyposis colorectal cancer
(HNPCC) harbour potentially pathogenic mutations in
MMR genes, particularly in hMLH1 and hMSH2 [3]. The
disease manifests with high mortality rate if not detected
and treated early, therefore presymptomatic genetic test-
ing is required [4]. However, the functional effects of
MMR mutations need to be characterized first. This is
essential, not only for effective diagnosis of cancer predis-
position, but also for choosing the appropriate chemo-
therapy, since it is known that MMR mutations can cause
resistance to chemotherapeutic agents by insufficient
induction of apoptosis [5].
There are over 450 germline allelic variants of hMLH1 and
hMSH2 genes known to date and more are being found,
but the functional relevance of each is very difficult to
establish on clinical samples alone. Therefore many in
vitro and in vivo assays have been developed for MMR gene
mutation analysis, using various molecular genetics tools
[6-16]. An in vitro functional analysis - involving Western
immunoblotting - of four hMLH1 mutations found in
HNPCC patients was described by Belvederesi et al. [6].
Several other strategies have been based on analysing the
interaction between MMR variants, using the yeast two-
hybrid system [7,8]. One recent study described the char-
acterization of MLH1 variants in terms of multiple func-
tional properties (e.g. protein expression/stability, nuclear
localization, protein-protein interaction and MMR effi-
ciency) [9]. In vivo assays have been performed in bacterial
and yeast model systems, all of them using expression vec-
tors with human MMR gene variants [10-13]. An alterna-
tive, commonly reported approach in yeast is the use of
vectors with yeast MMR orthologs harbouring a mutation
corresponding to those found in HNPCC patients, but the
method is limited by the degree of homology between
human and yeast genes [14,15]. MLH1 variants were also
introduced into human cell lines to analyze their effects
on apoptosis, proliferation, and regulation of mRNA
expression, as well as expression of interacting proteins
[16].
Although these studies have provided valuable clues to a
better understanding of MLH1 variants, it is difficult to
establish and compare their clinical relevance since a vari-
ety of strategies have been used. We believe that for relia-
ble interpretation of functional effects of MLH1 gene
mutations and their classification, all MLH1 mutations
extending within the whole gene coding region should be
analyzed using the same approach. In this study we are
proposing a novel in vivo approach to determine the func-
tional significance of hMLH1 mutations throughout the
whole coding region of the gene. The hPMS2 and hMLH1
genes, whose proteins form the hMutLα complex, were
each introduced into the yeast chromosome, replacing the
yeast orthologs. Direct chromosomal integration enabled
just one copy of a target gene to be introduced per cell.
Both human orthologs were under control of the yeast
promoter, and the original yeast genetic background was
preserved. The functionality of mismatch repair was
examined using a quantitative in vivo DNA MMR assay. To
assess the functionality of the novel test system, nine dif-
ferent MLH1 amino acid replacements were introduced in
vivo and evaluated for their pathogenicity. Results show
that our in vivo yeast-based approach can help assess the
pathogenic potential of cancer-related hMLH1 variants.
Methods
Yeast strain and vectors
The yeast Saccharomyces cerevisiae haploid strain used
was W303-1A/RE966 (MATa ade2 can1-100 his3-11,15
leu2-3, 112 trp1-1 ura3-1) [17]. Cells were maintained in
standard rich medium (YPD) [yeast extract/peptone/dex-
trose] and in selective synthetic medium (SD) [YNB:
0,67% w/v yeast nitrogen base, 2% w/v dextrose] supple-
mented with amino acids, depending on the auxotrophic
requirements, and grown at 30°C. Media were solidified
by addition of 2% w/v bacto-agar. The E. coli DH5α strain
was used as bacterial host for plasmid propagation. Plas-
mid pCORE with KlURA3-kanMX4 counter-selectable
reporter marker cassette (CORE) and plasmid pSH91 were
provided by Francesca Storici [18] and Thomas D. Petes
[19], respectively. The yeast expression vector pSH91 used
for in vivo MMR assay contains an in-frame (GT)16.5 tract
in the URA3 coding region. hMLH1 [GeneBank:
NM000249] and hPMS2 [GeneBank: NM000535] cDNAs
were obtained from pCMV-SPORT6 vector (ATCC, MGC-
5172) and pSG-PMS2-wt, respectively. The latter plasmid
was provided by Bert Vogelstein and Kenneth W. Kinzler
[20]. Expression of yeast URA3 gene in pSH91 is under
LEU2 gene promoter, so all test strains were transformed
with Yep181 vector expressing LEU2 gene for restoration
of leucine prototrophy [21].
Construction of humanized yeast strains
A »delitto perfetto« method was used for constructing
humanized yeast strains, as described by Storici et al. [18].
Delitto Perfetto is a two step approach for in vivo site-
directed mutagenesis in yeast, using highly proficient
homologous recombination system of S cerevisiae. The
first step involves integration of a counterselectable
(CORE) cassette in the region of interest. Subsequently,
the CORE cassette is replaced with DNA fragment con-
taining the mutation or the gene of interest (Figure 1). The
CORE cassette allows the selection of yeast cells that
receive the cassette during the first step, as well as selec-
tion of cells that lose the cassette in the second step of the
process.Page 2 of 9
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sette with KlURA3 and kanMX4 was amplified from
pCORE and integrated into yeast chromosome XIII after
the stop codon of the yMLH1 coding region (Figure 1A).
60- to 70-meric oligonucleotides (Sigma-Aldrich), con-
sisting of 40- to 50-nucleotide flanking regions homolo-
gous with the appropriate yeast genomic target locus and
a 20-nucleotide tract required for amplification from the
vector were used for the amplification. DNA fragments
were amplified by the polymerase chain reaction (PCR)
using Platinum® Pfx DNA polymerase (Invitrogen) and
introduced into yeast cells with the LiAc transformation
protocol [22]. Yeast clones that integrated CORE cassette
into their genome were selected on YPD plates containing
200 μg/mL of geneticin (G418; Sigma-Aldrich). The
CORE cassette was then completely removed by introduc-
ing complete hMLH1 cDNA into the yeast cells. Human
MLH1 cDNA was previously amplified from pCMV-
SPORT6 vector using 60-meric oligonucleotides. After
transformation, the resulting Ura-cells, which lost CORE
cassette, were isolated from synthetic complete medium
containing 1 mg/L 5-fluororotic acid monohydrate (5-
FOA; Toronto Research Chemicals Inc.). Isolated clones
(strain MV200) were identified by PCR, using Taq
polymerase (Eppendorf® Master Mix), and the nucleotide
sequences of the constructs were confirmed by DNA
sequencing (Sequiserve).
To replace yPMS1 by hPMS2 directly on the chromosome
(strain MV300), the CORE cassette was amplified with 60-
meric oligonucleotides from pCORE and introduced after
the stop codon of the yPMS1 gene in the yeast chromo-
some. The integrated CORE cassette, together with the
yPMS1 gene, was then replaced by hPMS2 cDNA, previ-
ously amplified from vector pSG-PMS2-wt with oligonu-
cleotides targeting yeast chromosome XIV. PCR products
were introduced into the yeast cells and clones were iso-
lated as described above. In order to obtain a yeast strain
containing both hMLH1 and hPMS2 (strain MV400), the
replacement of yMLH1 with hMLH1 was done in the
strain MV300 already harbouring hPMS2.
The yeast mlh1::kanMX gene disruption was constructed
by replacing the entire yMLH1 gene coding region with
kanMX gene amplified from pFA6aKanMX4. Clones
(strain MV100) were selected on YPD plates containing
G418 and identified by PCR.
When constructing MLH1 single-nucleotide substitutions
(Figure 1B), the CORE cassettes were amplified from
pCORE with oligonucleotides targeting the human
ortholog at the relevant codons. Integrative 3'-overlap-
ping recombinant oligonucleotides harbouring the
desired single-nucleotide substitutions were extended in
vitro as described by Storici et al [18]. PCR products were
again transformed into appropriate geneticin resistant
yeast cells and clones were isolated as described above. All
oligonucleotide sequences are available upon request.
In vivo MMR assay and statistical analysis
The standardized in vivo MMR assay has been described in
detail elsewhere [23]. The assay is based on stability of 33
bp GT tract, which is inserted in-frame the yeast URA3
gene in plasmid pSH91, as a measure of MMR efficiency.
Instability of dinucleotide repeat is associated with DNA
polymerase slipping during replication and alterations in
tract length result in ura3 mutants, if not repaired by
MMR. Mutant ura3 cells can be measured by their resist-
ance to 5-FOA. Expression of the yeast URA3 gene in
pSH91 is under LEU2 gene promoter, so all strains have to
be leucine prototrophs.
In brief, plasmids pSH91 and Yep181 were first trans-
formed [24] into the prepared yeast strains. At least 12 col-
onies of each analyzed yeast strain were picked from
selective media plates (lacking tryptophan, leucine and
uracil) and grown to saturation in SD supplemented with
Constructing humanized yeast strains with delitto perfetto systemFigure 1
Constructing humanized yeast strains with delitto 
perfetto system. A. Replacing yeast MMR (yMMR) genes 
(i.e. yMLH1 and yPMS1) with their human orthologs (hMMR). 
First, the CORE cassette was introduced into yeast chromo-
some (line) after the stop codon of a yeast MMR gene, ena-
bling the yeast gene to be still active during the second step 
of the process. Next, together with CORE cassette, the 
yeast gene was replaced with its human ortholog. B. Intro-
ducing missense alterations into hMLH1 gene in strain co-
expressing hMLH1 and hPMS2 genes. First, the CORE cas-
sette was introduced into hMLH1, replacing nucleotide of 
interest (black vertical line). Next, the CORE cassette was 
replaced by DNA fragment harbouring a single-nucleotide 
alteration (yellow vertical line). Genetic technique, delitto per-
fetto, is based on recombination event (grey area) between 
two identical strand of DNA.
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were homogeneous for URA3 cells with in-frame GT
tracts. Cultures were diluted 1:1000 into SD supple-
mented with adenine, histidine and uracil, and grown to
OD660 of 1. This allowed growth of all cells, including
newly arising ura3 mutants. Each culture was then serially
diluted and plated on SD plates supplemented with ade-
nine, histidine and uracil, and the number of colonies was
counted after a 3-day incubation to determine cell con-
centration. 100 μL aliquots of undiluted culture were
plated on SD plates supplemented with adenine, histidine
and uracil and containing 5-FOA. Colonies were counted
after 3 days to calculate the concentration of ura3
mutants. Strains with increased instability of the GT tract,
due to a disrupted MMR system, resulted in the ura3
mutant strain. Mutation rates were calculated using the
method of the median [25]. For statistical analysis, Mann-
Whitney tests were performed between all strains using
GraphPad-InStat software. Differences in mutation rates
were considered significant when P ≤ 0.05.
Results
Characterization of human MMR genes in yeast
For functional analysis of HNPCC-related hMLH1 vari-
ants we prepared several humanized yeast strains with
hPMS2 and different hMLH1 variants inserted into the
genome and replacing their yeast orthologs. The function
of the human MLH1 protein variants was determined
with a standardized in vivo MMR assay measuring stability
of the (GT)16.5 tract in vivo. A MV100 strain was con-
structed by integrating kanMX gene into the coding region
of the yeast MLH1. By this intervention the ability of MMR
to repair insertion/deletion loops on microsatellite GT
tract was completely disrupted, with 79-fold greater muta-
tion rate than in the wild-type (Figure 2).
For in vivo replacement of the yeast MLH1 gene by its
human ortholog, we first integrated the CORE cassette
into the yeast MLH1 gene. Experiments replacing the
CORE cassette at codon 73 of the yeast MLH1 coding
region with complete human MLH1 cDNA failed (data
not shown). It was shown before in yeast, that MLH1 can
play a role in regulating mitotic recombination [26] and
we believe that its disruption, in our case by the integrated
CORE cassette, could have a negative impact on recombi-
nation events needed for successful replacement of the
cassette. For this reason we engineered an alternative gene
fusion by integrating the CORE cassette after the yeast
MLH1 stop codon, thus maintaining the integrity of the
yeast gene. Replacement of this fusion construct with the
complete human MLH1 cDNA was now feasible. How-
ever, human MLH1 alone did not complement the yeast
ortholog and exhibited a 28-fold increase in mutation rate
over the wild-type (Figure 2). Using the same strategy we
then replaced the yeast PMS1 with the complete human
PMS2 cDNA in the strain harbouring the hMLH1 gene.
Co-expression of human MLH1 and PMS2 (strain
MV400) indicated that the exogenous hMLH1-hPMS2
complex was able to fully restore the MMR function in
yeast cells (Figure 2). Mutation rate was the same as
observed in the wild-type strain (P = 0.89). However, the
MV300 strain expressing hPMS2 alone exhibited a 40-fold
higher mutation rate than that in the wild-type parental
strain.
The described system is operational for functional 
characterization of hMLH1 alterations
Our approach was shown to be operational for functional
analysis of hMLH1 mutations by assessing eight different
hMLH1 missense mutations found in cancer patients. Two
variants (T117M and I219V) have already been evaluated
by several different functional assays (Table 1). Because of
the consistency of data obtained from the assays and their
correlation with clinical reports, these variants were
included as experimental controls in our study. We further
analyzed the impact on phenotype of six missense muta-
tions (A92P, S93G, K618R, K618T, Y646C and R659Q).
An additional, non-cancer-associated frameshift mutation
(1955 del 1 bp), which determines an early stop codon at
position 660, was used to evaluate the impact of a clear
loss-of-function mutation. All nucleotide rearrangements
resulting in relevant codon changes were introduced in
vivo into strain MV400 co-expressing hMLH1 and hPMS2
genes.
The results of functional characterization of the hMLH1
variants are presented in Table 2. The amino acid altera-
tion A92P did not alter MMR function, since the mutation
rate was the same as observed in the wild-type parental
MV400 strain. The 1.8-fold greater mutation rate in the
strain expressing K618T variant, in comparison with the
parental MV400 strain, was also not significant (P = 0.69).
Six of the hMLH1 codon changes analyzed encode pro-
teins which were observed in this study to support inter-
mediate efficiencies of DNA MMR. The mutation rates
measured in strains expressing hMLH1 variants S93G,
T117M, I219V, K618R, Y646C and R659Q were signifi-
cantly lower than in the mlh1 deficient yeast strain MV100
(P < 0.0001). Mutation rates of T117M, Y646C and
R659Q were also clearly (P < 0,0001) greater (12.3-, 15.8-
and 7.9-fold, respectively) than those obtained in the
strain MV400 co-expressing wild-type human orthologs.
A frameshift mutation 1955 del 1 bp, an experimental
control never reported in HNPCC-patients, exhibited
complete loss of MMR activity as expected. The alteration
conferred a 82.7-fold higher mutation rate, than exhibited
by the wild-type parental MV400 strain.
Discussion
Hundreds of hMLH1 alterations have been found in
HNPCC patients and for many, especially those leading to
amino acid substitutions, the pathogenicity is still diffi-Page 4 of 9
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be functionally characterized. For this purpose, a number
of yeast-based assays evaluating the functional signifi-
cance of MMR variants have been developed, based on the
fact that MMR has been conserved throughout eukaryotic
evolution. Because of conservation of cellular functions
from yeast to mammals and the ease of genetic manipula-
tion in yeast S cerevisiae, this unicellular organism has
been used before for assessing patogenicity of other can-
cer-related genes (eg. BRCA1 and p53) [27,28]. Besides
many in vitro functional assays that require separate char-
acterization of multiple functional properties [9,12], in
vivo tests have been developed which appear to be more
reliable [7,10,11,13]. However, it is important to note
that, with known in vivo yeast assays, only mutations
occurring in evolutionarily conserved regions in humans
and yeast could be functionally analyzed, due to the lack
of homology between human and yeast genes [14,15].
Moreover, clinical data associated with the disease usually
lack to correlate with functional analysis data (for refer-
ences see Table 1). Considering the fact that the efficiency
of mismatch repair is highly affected by the degree of
expression of the MLH1 gene [15] (variable in an episo-
mal way), we have proposed a yeast-based in vivo system
co-expressing chromosome-integrated human MLH1 and
human PMS2 genes. With this intervention, the expres-
sions of both human genes were controlled by the orthol-
ogous yeast promoters. Besides that, the expression of
gene in chromosome seems to be region-depended.
Higher-expressed and lower-expressed regions have been
reported along yeasts' chromosome III. Moreover, the sta-
bility of foreign gene in chromosome is better than that in
plasmids [29].
The MLH1 protein contains an amino-terminal ATPase
domain and a carboxy-terminal domain. According to
Ellison's conclusion [10] and to our unpublished data, the
human ATP domain is functional in yeast. The human
ortholog alone does not restore MMR activity in mlh1-
deficient yeast cells when expressed episomally [13]. The
same appeared to be true with the chromosomal integra-
tion of the entire hMLH1 performed in our study (Figure
2). However, additional replacement of yeast PMS1 with
hPMS2 (which encodes a heterodimeric partner of
hMLH1) directly on the yeast chromosome, in a strain
The MMR efficiency in yeast strains harbouring endogenous and/or human MMR genesFigure 2
The MMR efficiency in yeast strains harbouring endogenous and/or human MMR genes. Each datum is the mean, 
with a 95% confidence interval indicated, of three independent experiments. Mean mutation rates are: Wild-type 2.19 × 10-6 ; 
MV100 1.74 × 104; MV200 6.05 × 10-5; MV300 8.86 × 10-5; MV400 2.25 × 10-6. Genotypes of strains are boxed. All prepared 
strains originated from W303 background [17].


















MV400 mlh10::hMLH1 pms10::hPMS2Page 5 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:382 http://www.biomedcentral.com/1471-2407/9/382
Page 6 of 9
(page number not for citation purposes)
Table 1: Comparison of published functional and clinical data on hMLH1 variants
MLH1 alteration Functional and biochemical assays Clinical data
Assay type Outcomea MSIb MLH1 IHCc Aged Family history/segregation Ref.
A92Pe [30]
S93G In vivo MMR assay [11,10] - - 70 YES/ [9]
In vitro MMR assay [11,9,3] - - - YES POS 90 YES/ [32]
In vitro protein interaction assay [9,3] - - YES NEG 53 YES/ [32]
MLH1 expression/localization [11,9] - - [33]
65 YES/YES [3]
T117Me In vivo MMR assay [11,13] + + YES [34]
In vitro MMR assay [11,12] + + 40 YES/ [35]
In vivo protein interaction assay [7] + YES NEG 43 YES/ [36]
In vitro protein interaction assay [7,12] ± ± NO POS 42 YES/ [36]
MLH1 expression/localization 
[11,7,13,16]
+ + + + YES YES/ [37]
YES POS 55 YES/ [38]
YES NEG [39]
I219V In vivo MMR assay [11,13] - - POS 55 [36]
In vitro MMR assay [11,9,12] - - -
In vivo protein interaction assay [7] -
In vitro protein interaction assay [9,12] - -
MLH1 expression/localization [11,9] ± -
K618Re YES NEG [40]
< 50 NO/ [41]
K618Te In vivo MMR assay [11,13] + + NO POS YES/NO [43]
In vitro MMR assay [11,9] ± - NO POS YES/NO [44]
In vivo protein interaction assay [7] - 42 NO/ [45]
In vitro protein interaction assay 
[7,42,9,12]
+ + - +
MLH1 expression/localization 
[11,7,13,9]
± ± ± ±
Y646C In vitro MMR assay [9] - YES NEG 48 YES/ [46]
In vitro protein interaction assay [9,6] - + YES NEGf 36 YES/ [9,47]
MLH1 expression/localization [9,6] - - YES NEG 48 YES/ [6]
YES NEG 51 YES/ [6]
R659Qe In vivo MMR assay [11] ± YES NEG 32 YES/ [9]
In vitro MMR assay [11,9] - -
In vitro protein interaction assay [9] -
MLH1 expression/localization [11,9] ± -
aThe outcome of each assay is given: +, pathogenic; -, non-pathogenic; ±, inconclusive. Each symbol refers to the assay referenced in section: Assay 
type.
bMicrosatellite instability.
cImmunohistochemical staining of MLH1: POS, positive; NEG, negative.
dPatients' age at cancer onset.
eThe variant was also found in patients carrying a second MMR alteration. Those patients were excluded from the Table.
fImmunohistochemical staining of PMS2. In this case MLH1 staining was positive.
BMC Cancer 2009, 9:382 http://www.biomedcentral.com/1471-2407/9/382expressing human MLH1 protein, resulted in complete
restoration of MMR function (Figure 2).
Co-expression of human MLH1 and PMS2 proved to be
effective for evaluating the pathogenicity of alterations
found throughout the coding region of human MLH1
gene. Nine different hMLH1 alterations were shown to
bring about from little or no effect on protein function to
complete loss of MMR activity (Table 2). Before interpret-
ing the pathogenicity of these MLH1 alterations, the
appropriate tolerance level for functional proficiency had
to be established. For this reason, hMLH1 missense alter-
ation I219V was included in the assay as the functional
control. This hMLH1 modification is a known harmless
polymorphism consistently reported to have no func-
tional effect on MLH1 (for reference see Table 1). In our
test system the variant exhibited a significantly greater
mutation rate than the wild-type. We therefore propose
that 3-fold increase in mutation rate over the wild-type is
the reasonable threshold between harmless variants on
one side, and the variants with reduced MMR activity that
may contribute to cancer susceptibility on the other side
of a threshold. The proposed treshold might change, as
the pathogenicities of more variants with proven pheno-
types are assessed with the described approach.
Accordingly, the amino acid changes A92P, S93G, K618R
and K618T were classified as non-pathogenic variations
(Table 2). S93G is associated with a late age of onset, but
has been reported in biochemical studies to have no func-
tional effect on MLH1. The latter was confirmed in our
study. The alteration K618T has been functionally charac-
terized with various biological tools, with controversial
results as to its pathogenicity. Our results correlate with
clinical studies, in which K618T was reported not to co-
segregate with the disease and in which affected carriers
showed microsatellite stability and normal immunohisto-
chemical staining of MLH1. (Table 1). Modifications
A92P and K618R were functionally characterized for the
first time. The novel amino acid change A92P was found
in a patient with gastric carcinoma, and reported as prob-
ably pathogenic from its predicted structural changes [30].
The K618R modification was identified in colorectal can-
cer patients, however the clinical data are rather incom-
plete. The results of our assay suggest that these two
modifications may not be causally associated with the
observed clinical phenotype in mutation carriers (Table
1). Nevertheless, A92P, S93G, K618R and K618T must not
be considered as absolutely non-pathogenic. Some altera-
tions, despite being functionally proficient, exhibited
reduction of protein efficiency that was significant com-
pared to the wild-type, and mutation carriers may still,
with low penetrance, express a particular phenotype.
Therefore functional data have to be considered carefully
alondside clinical studies that need to be undertaken with
much more caution.
According to our assay, a further four alterations, includ-
ing the functional control - a frameshift mutation 1995
del 1 bp - should be considered as pathogenic variants. As
assumed before, the missense mutations did not com-
pletely destroy protein function and are thus expected to
Table 2: Functional characterization of hMLH1 variants in the in vivo yeast-based system




Summary of other 
functional studies
Summary of clinical 
data
Missense variant
A92P 274G>CA 2.07 × 10-6
(1.17 × 10-6 - 2.96 × 10-6)
non-pathogenic
S93Gb 277A>G 6.22 × 10-6




T117M 350C>T 2.76 × 10-5
(1.28 × 10-5 - 4.23 × 10-5)
pathogenic pathogenic pathogenic
I219V 655A>G 6.50 × 10-6




K618Rb 1853A>G 4.99 × 10-6




K618Ta 1853A>C 3.97 × 10-6
(1.78 × 10-6 - 6.16 × 10-6)
non-pathogenic inconclusive non-pathogenic
Y646C 1937A>G 3.54 × 10-5
(1.78 × 10-5 - 5.31 × 10-5)
pathogenic non-pathogenic pathogenic
R659Q 1976G>A 1.77 × 10-5
(8.52 × 10-6 - 2.70 × 10-5)
pathogenic non-pathogenic pathogenic
Frameshift mutation
1955 del 1 bp 1.86 × 10-4
(1.30 × 10-4 - 2.43 × 10-4)
loss-of-function
aThis variant is functionally indistinguishable from the wild-type (P > 0.05).
bFunctional significance of the variant did not correlate with available clinical data.Page 7 of 9
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we confirmed previous reports showing that the T117M
variant may be associated with pathogenicity in HNPCC
(Table 1). Functional characterization of another two var-
iants (Y646C and R659Q) was, however, not consistent
with other functional studies, in which they were identi-
fied as non-pathogenic (Table 2). However, carriers of
these variants developed cancer at early-middle age and
showed HNPCC clinical features (Table 1). The discrep-
ancy between our assay and previous functional studies
can be explained by the conclusion that subtle functional
alterations may not be revealed with in vitro biological
tools [9]. In our study, complete elimination of MMR
function was only established with the frameshift muta-
tion 1995 del 1 bp.
Conclusion
We have shown, in contrast to in vitro studies, that co-
employing the chromosome-integrated hMLH1 and
hPMS2 genes in yeast not only enabled pathogenic MLH1
variants to be discriminated from polymorphisms that
have no effect on MMR function, but also enabled vari-
ants resulting in reduced MMR activity to be identified
and functionally classified. Moreover, the results corre-
lated with clinical data in five out of seven hMLH1 vari-
ants. Our yeast-based in vivo system may thus be used for
functional characterization of variants with incomplete
clinical data, since precise quantification of MLH1 vari-
ants is critical for effective early diagnosis and prognosis,
as well as for genetic counselling of affected individuals.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MV participated in the design of the study, performed the
statistical analysis and drafted the manuscript. MV and NZ
carried out the experiments. AC and PH participated in
the design of the study. RK coordinated the study and
helped to draft the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We thank Drs. Francesca Storici and Thomas D. Petes for kindly providing 
pCORE and pSH91 plasmids, and Drs. Bert Vogelstein and Kenneth W. 
Kinzler for providing pSG-PMS2-wt plasmid. We thank Jelka Lenarcic for 
excellent technical assistance. The authors are grateful to Professor Bill 
Milne and Professor Roger Pain for critical reading of the manuscript. This 
work was supported by grant P1-0104 from ARRS and a JI grant to author 
MV.
References
1. Vogelstein B, Kinzler KW: Cancer genes and the pathways they
control.  Nat Med 2004, 10:789-799.
2. Loeb LA, Loeb KR, Anderson JP: Multiple mutations and cancer.
Proc Natl Acad Sci USA 2003, 100:776-781.
3. Nystrom-Lahti M, Perrera C, Raschle M, Panyushkina-Seiler E, Marra
G, Curci A, Quaresima B, Costanzo F, D'Urso M, Venuta S, Jiricny J:
Functional analysis of MLH1 mutations linked to hereditary
nonpolyposis colon cancer.  Genes Chromosomes Cancer 2002,
33:160-167.
4. Jiricny J, Nystrom-Lahti M: Mismatch repair defects in cancer.
Curr Opin Genet Dev 2000, 10:157-161.
5. Clodfelter JE, M BG, Drotschmann K: MSH2 missense mutations
alter cisplatin cytotoxicity and promote cisplatin-induced
genome instability.  Nucleic Acids Res 2005, 33:3323-3330.
6. Belvederesi L, Bianchi F, Loretelli C, Gagliardini D, Galizia E, Bracci R,
Rosati S, Bearzi I, Viel A, Cellerino R, Porfiri E: Assessing the path-
ogenicity of MLH1 missense mutations in patients with sus-
pected hereditary nonpolyposis colorectal cancer:
correlation with clinical, genetic and functional features.  Eur
J Hum Genet 2006, 14:853-859.
7. Kondo E, Suzuki H, Horii A, Fukushige S: A yeast two-hybrid assay
provides a simple way to evaluate the vast majority of
hMLH1 germ-line mutations.  Cancer Res 2003, 63:3302-3308.
8. Mac Partlin M, Homer E, Robinson H, McCormick CJ, Crouch DH,
Durant ST, Matheson EC, Hall AG, Gillespie DA, Brown R: Interac-
tions of the DNA mismatch repair proteins MLH1 and MSH2
with c-MYC and MAX.  Oncogene 2003, 22:819-825.
9. Raevaara TE, Korhonen MK, Lohi H, Hampel H, Lynch E, Lonnqvist
KE, Holinski-Feder E, Sutter C, McKinnon W, Duraisamy S, et al.:
Functional significance and clinical phenotype of nontruncat-
ing mismatch repair variants of MLH1.  Gastroenterology 2005,
129:537-549.
10. Ellison AR, Lofing J, Bitter GA: Functional analysis of human
MLH1 and MSH2 missense variants and hybrid human-yeast
MLH1 proteins in Saccharomyces cerevisiae.  Hum Mol Genet
2001, 10:1889-1900.
11. Takahashi M, Shimodaira H, Andreutti-Zaugg C, Iggo R, Kolodner RD,
Ishioka C: Functional analysis of human MLH1 variants using
yeast and in vitro mismatch repair assays.  Cancer Res 2007,
67:4595-4604.
12. Trojan J, Zeuzem S, Randolph A, Hemmerle C, Brieger A, Raedle J,
Plotz G, Jiricny J, Marra G: Functional analysis of hMLH1 vari-
ants and HNPCC-related mutations using a human expres-
sion system.  Gastroenterology 2002, 122:211-219.
13. Shimodaira H, Filosi N, Shibata H, Suzuki T, Radice P, Kanamaru R,
Friend SH, Kolodner RD, Ishioka C: Functional analysis of human
MLH1 mutations in Saccharomyces cerevisiae.  Nat Genet
1998, 19:384-389.
14. Drotschmann K, Clark AB, Kunkel TA: Mutator phenotypes of
common polymorphisms and missense mutations in MSH2.
Curr Biol 1999, 9:907-910.
15. Shcherbakova PV, Hall MC, Lewis MS, Bennett SE, Martin KJ, Bushel
PR, Afshari CA, Kunkel TA: Inactivation of DNA mismatch
repair by increased expression of yeast MLH1.  Mol Cell Biol
2001, 21:940-951.
16. Brieger A, Trojan J, Raedle J, Plotz G, Zeuzem S: Transient mis-
match repair gene transfection for functional analysis of
genetic hMLH1 and hMSH2 variants.  Gut 2002, 51:677-684.
17. Rothstein RJ: One-step gene disruption in yeast.  Methods Enzy-
mol 1983, 101:202-211.
18. Storici F, Lewis LK, Resnick MA: In vivo site-directed mutagene-
sis using oligonucleotides.  Nat Biotechnol 2001, 19:773-776.
19. Strand M, Prolla TA, Liskay RM, Petes TD: Destabilization of
tracts of simple repetitive DNA in yeast by mutations affect-
ing DNA mismatch repair.  Nature 1993, 365:274-276.
20. Parsons R, Li GM, Longley M, Modrich P, Liu B, Berk T, Hamilton SR,
Kinzler KW, Vogelstein B: Mismatch repair deficiency in pheno-
typically normal human cells.  Science 1995, 268:738-740.
21. Gietz RD, Sugino A: New yeast-Escherichia coli shuttle vectors
constructed with in vitro mutagenized yeast genes lacking
six-base pair restriction sites.  Gene 1988, 74:527-534.
22. Wach A, Brachat A, Pohlmann R, Philippsen P: New heterologous
modules for classical or PCR-based gene disruptions in Sac-
charomyces cerevisiae.  Yeast 1994, 10:1793-1808.
23. Polaczek P, Putzke AP, Leong K, Bitter GA: Functional genetic
tests of DNA mismatch repair protein activity in Saccharo-
myces cerevisiae.  Gene 1998, 213:159-167.
24. Gietz RD, Woods RA: Transformation of yeast by lithium ace-
tate/single-stranded carrier DNA/polyethylene glycol
method.  Methods Enzymol 2002, 350:87-96.
25. Lea DE, Coulson CA: The contribution of the number of
mutants in bacterial populations.  Journal of Genetics 1948,
49:264-285.Page 8 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:382 http://www.biomedcentral.com/1471-2407/9/382Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
26. Nicholson A, Hendrix M, Jinks-Robertson S, Crouse GF: Regulation
of mitotic homeologous recombination in yeast. Functions
of mismatch repair and nucleotide excision repair genes.
Genetics 2000, 154:133-146.
27. Caligo MA, Bonatti F, Guidugli L, Aretini P, Galli A: A yeast recom-
bination assay to characterize human BRCA1 missense var-
iants of unknown pathological significance.  Hum Mutat 2009,
30:123-133.
28. Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, Schmidt S, Iggo R:
Screening patients for heterozygous p53 mutations using a
functional assay in yeast.  Nat Genet 1993, 5:124-129.
29. Yamane S, Yamaoka M, Yamamoto M, Maruki T, Matsuzaki H, Hatano
T, Fukui S: Region specificity of chromosome III on gene
expression in the yeast Saccharomyces cerevisiae.  J Gen Appl
Microbiol 1998, 44:275-281.
30. Hudler P, Vouk K, Liovic M, Repse S, Juvan R, Komel R: Mutations
in the hMLH1 gene in Slovenian patients with gastric carci-
noma.  Clin Genet 2004, 65:405-411.
31. Tomlinson IP, Beck NE, Homfray T, Harocopos CJ, Bodmer WF:
Germline HNPCC gene variants have little influence on the
risk for sporadic colorectal cancer.  J Med Genet 1997, 34:39-42.
32. Hendriks Y, Franken P, Dierssen JW, De Leeuw W, Wijnen J, Dreef
E, Tops C, Breuning M, Brocker-Vriends A, Vasen H, et al.: Conven-
tional and tissue microarray immunohistochemical expres-
sion analysis of mismatch repair in hereditary colorectal
tumors.  Am J Pathol 2003, 162:469-477.
33. Quaresima B, Grandinetti C, Baudi F, Tassone P, Barbieri V, Conforti
S, Avvedimento EV, Costanzo F, Venuta S: Hereditary nonpolypo-
sis coloretal cancer: identification of novel germline muta-
tions in two kindreds not fulfulling the Amsterdam criteria.
Mutations in brief no. 203. Online.  Hum Mutat 1998, 12:433.
34. Raedle J, Brieger A, Trojan J, Hardt T, Herrmann G, Zeuzem S: Eval-
uation of rapid microsatellite analysis of paraffin-embedded
specimens in screening for hereditary nonpolyposis colorec-
tal cancer.  Mod Pathol 1999, 12:485-491.
35. Buerstedde JM, Alday P, Torhorst J, Weber W, Muller H, Scott R:
Detection of new mutations in six out of 10 Swiss HNPCC
families by genomic sequencing of the hMSH2 and hMLH1
genes.  J Med Genet 1995, 32:909-912.
36. Ward R, Meldrum C, Williams R, Mokany E, Scott R, Turner J,
Hawkins N, Burgess B, Groombridge C, Spigelman A: Impact of
microsatellite testing and mismatch repair protein expres-
sion on the clinical interpretation of genetic testing in hered-
itary non-polyposis colorectal cancer.  J Cancer Res Clin Oncol
2002, 128:403-411.
37. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson
P, Jass JR, Dunlop M, Wyllie A, Peltomaki P, et al.: Analysis of mis-
match repair genes in hereditary non-polyposis colorectal
cancer patients.  Nat Med 1996, 2:169-174.
38. Dieumegard B, Grandjouan S, Sabourin JC, Le Bihan ML, Lefrere I,
Bellefqih , Pignon JP, Rougier P, Lasser P, Benard J, et al.: Extensive
molecular screening for hereditary non-polyposis colorectal
cancer.  Br J Cancer 2000, 82:871-880.
39. Plevova P, Krepelova A, Papezova M, Sedlakova E, Curik R, Foretova
L, Navratilova M, Novotny J, Zapletalova J, Palas J, et al.: Immunohis-
tochemical detection of the hMLH1 and hMSH2 proteins in
hereditary non-polyposis colon cancer and sporadic colon
cancer.  Neoplasma 2004, 51:275-284.
40. Plaschke J, Kruger S, Pistorius S, Theissig F, Saeger HD, Schackert HK:
Involvement of hMSH6 in the development of hereditary
and sporadic colorectal cancer revealed by immunostaining
is based on germline mutations, but rarely on somatic inac-
tivation.  Int J Cancer 2002, 97:643-648.
41. Yuan Z, Legendre B Jr, Sreeramoju P, Lowes C, Reynolds D, Bennett
A, Kent TS, Miller A, Zhu J, Weber TK: A novel mutation detec-
tion approach of hMLH1 and hMSH2 genes for screening of
colorectal cancer.  Cancer Detect Prev 2006, 30:333-340.
42. Guerrette S, Acharya S, Fishel R: The interaction of the human
MutL homologues in hereditary nonpolyposis colon cancer.
J Biol Chem 1999, 274:6336-6341.
43. Genuardi M, Carrara S, Anti M, Ponz de Leon M, Viel A: Assessment
of pathogenicity criteria for constitutional missense muta-
tions of the hereditary nonpolyposis colorectal cancer genes
MLH1 and MSH2.  Eur J Hum Genet 1999, 7:778-782.
44. Cravo M, Afonso AJ, Lage P, Albuquerque C, Maia L, Lacerda C,
Fidalgo P, Chaves P, Cruz C, Nobre-Leitao C: Pathogenicity of
missense and splice site mutations in hMSH2 and hMLH1
mismatch repair genes: implications for genetic testing.  Gut
2002, 50:405-412.
45. Rossi BM, Lopes A, Oliveira Ferreira F, Nakagawa WT, Napoli Fer-
reira CC, Casali Da Rocha JC, Simpson CC, Simpson AJ: hMLH1 and
hMSH2 gene mutation in Brazilian families with suspected
hereditary nonpolyposis colorectal cancer.  Ann Surg Oncol
2002, 9:555-561.
46. Scartozzi M, Bianchi F, Rosati S, Galizia E, Antolini A, Loretelli C, Piga
A, Bearzi I, Cellerino R, Porfiri E: Mutations of hMLH1 and
hMSH2 in patients with suspected hereditary nonpolyposis
colorectal cancer: correlation with microsatellite instability
and abnormalities of mismatch repair protein expression.  J
Clin Oncol 2002, 20:1203-1208.
47. Nakagawa H, Lockman JC, Frankel WL, Hampel H, Steenblock K, Bur-
gart LJ, Thibodeau SN, de la Chapelle A: Mismatch repair gene
PMS2: disease-causing germline mutations are frequent in
patients whose tumors stain negative for PMS2 protein, but
paralogous genes obscure mutation detection and interpre-
tation.  Cancer Res 2004, 64:4721-4727.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/382/pre
pubPage 9 of 9
(page number not for citation purposes)
